On April 2, 2025, Edgewise Therapeutics announced positive top-line data from the Phase 2 CIRRUS-HCM trial of EDG-7500, showing significant reductions in heart failure biomarkers and improvements in patient quality of life without affecting heart function. The trial involved 29 participants and demonstrated promising results for both obstructive and nonobstructive hypertrophic cardiomyopathy.